Tissue invasive macrophage density is correlated with prognosis in cholangiocarcinoma

Molecular Medicine Reports

Volumn 3, Issue 4, 2010, Pages 597-605

  Subimerb, Chutima ^a   Pinlaor, Somchai ^a   Khuntikeo, Narong ^a   Leelayuwat, Chanvit ^a,b   Morris, Alanna ^c   McGrath, Michael S ^c   Wongkham, Sopit ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cholangiocarcinoma; MAC387; Macrophage; Prognostic marker; Survival

Indexed keywords

GELATINASE B; MACROPHAGE 387; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; EXTRACELLULAR MATRIX; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; METASTASIS; OVERALL SURVIVAL; POLYMORPHONUCLEAR CELL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 77955736266     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000303     Document Type: Article

References (31)

1. Balkwill F and Mantovani A: Inflammation and cancer: back to Virchow? Lancet 357: 539-545, 2001.
2. Lee AH, Happerfield LC, Bobrow LG and Millis RR: Angiogenesis and inflammation in invasive carcinoma of the breast. J Clin Pathol 50: 669-673, 1997.
3. Goede V, Brogelli L, Ziche M and Augustin HG: Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int J Cancer 82: 765-770, 1999.
4. Crowther M, Brown NJ, Bishop ET and Lewis CE: Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J Leukoc Biol 70: 478-490, 2001.
5. Goebeler M, Roth J, Teigelkamp S and Sorg C: The monoclonal antibody MAC387 detects an epitope on the calcium-binding protein MRP14. J Leukoc Biol 55: 259-261, 1994.
6. Brandtzaeg P, Jones DB, Flavell DJ and Fagerhol MK: Mac387 antibody and detection of formalin resistant myelomonocytic L1 antigen. J Clin Pathol 41: 963-970, 1988.
7. Bhamarapravati N and Thamavit W: Animal studies on liver-fluke infestation, dimethylnitrosamine and bileduct carcinoma. Lancet 1: 206-207, 1978.
8. Vatanasapt V, Tangvoraphonkchai V, Titapant V, Pipitgool V, Viriyapap D and Sriamporn S: A high incidence of liver cancer in Khon Kaen Province, Thailand. Southeast Asian J Trop Med Public Health 21: 489-494, 1990.
9. Pinlaor S, Hiraku Y, Ma N, et al: Mechanism of NO-mediated oxidative and nitrative DNA damage in hamsters infected with Opisthorchis viverrini: a model of inflammation-mediated carcinogenesis. Nitric Oxide 11: 175-183, 2004.
10. Greene FL, Page DL, Fleming ID, et al: AJCC Cancer Staging Manual. 6th edition. Springer-Verlag, New York, 2002.
11. Mantovani A, Allavena P and Sica A: Tumor-associated macrophage as a prototypic type II polarised phagocyte population: role in tumor progression. Eur J Cancer 40: 1660-1667, 2004.
12. Van Ginderachter JA, Movahedi K, Hassanzadeh Ghassabeh G, et al: Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. Immunobiology 211: 487-501, 2006.
13. Pulford KA, Rigney EM, Micklem KJ, et al: KP1: a new monoclonal antibody that detects a monocyte/macrophage associated antigen in routinely processed tissue sections. J Clin Pathol 42: 414-421, 1989.
14. Bardadin KA, Scheuer PJ, Peczek A and Wejman J: Immunocytochemical observations on macrophage populations in normal fetal and adult human liver. J Pathol 164: 253-259, 1991.
15. Uenishi T, Hirohashi K, Kubo S, Yamamoto T, Yamazaki O and Kinoshita H: Clinicopathological factors predicting outcome after resection of mass-forming intrahepatic cholangiocarcinoma. Br J Surg 88: 969-974, 2001.
16. Leong TYM, Wannakrairot P, Lee ES and Leong AS-Y: Pathology of cholangiocarcinoma. Curr Diag Pathol 13: 54-64, 2007.
17. Isa T, Kusano T, Shimoji H, Takeshima Y, Muto Y and Furukawa M: Predictive factors for long-term survival in patients with intrahepatic cholangiocarcinoma. Am J Surg 181: 507-511, 2001.
18. Ishigami S, Natsugoe S, Tokuda K, et al: Tumor-associated macrophage (TAM) infiltration in gastric cancer. Anticancer Res 23: 4079-4083, 2003. (Pubitemid 37474368)
19. Mantovani A, Sozzani S, Locati M, Allavena P and Sica A: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555, 2002.
20. Ben-Baruch A: Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res 5: 31-36, 2003.
21. Bingle L, Brown NJ and Lewis CE: The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196: 254-265, 2002.
22. Leek RD and Harris AL: Tumor-associated macrophages in breast cancer. Journal of Mammary Gland Biology and Neoplasia 7: 177-189, 2002.
23. Pollard J: Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4: 71-78, 2004.
24. Ogata Y, Itoh Y and Nagase H: Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases. J Biol Chem 270: 18506-18511, 1995.
25. Morodomi T, Ogata Y, Sasaguri Y, Morimatsu M and Nagase H: Purification and characterization of matrix metalloproteinase 9 from U937 monocytic leukaemia and HT1080 fibrosarcoma cells. Biochem J 285: 603-611, 1992.
26. Inuzuka K, Ogata Y, Nagase H and Shirouzu K: Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma. J Surg Res 93: 211-218, 2000.
27. Kim TD, Song KS, Li G, et al: Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer. BMC Cancer 6: 211, 2006.
28. Illemann M, Bird N, Majeed A, et al: MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases. Mol Cancer Res 4: 293-302, 2006.
29. Nemoto H, Rittling SR, Yoshitake H, et al: Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. J Bone Miner Res 16: 652-659, 2001.
30. Xu G, Sun W, He D, et al: Overexpression of osteopontin in rheumatoid synovial mononuclear cells is associated with joint inflammation, not with genetic polymorphism. J Rheumatol 32: 410-416, 2005.
31. Zheng W, Li R, Pan H, et al: Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1beta through the NF-kappaB and MAPK pathways in rheumatoid arthritis. Arthritis Rheum 60: 1957-1965, 2009.